3 Big Biotech Stocks Rising on Big Volume

DELAFIELD, Wis. (Stockpickr) -- Professional traders running mutual funds and hedge funds don't just look at a stock's price moves; they also track big changes in volume activity. Often when above-average volume moves into an equity, it precedes a large spike in volatility.

>>5 Huge Stocks to Trade This Week

Major moves in volume can signal unusual activity, such as insider buying or selling -- or buying or selling by "superinvestors."

Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst. These types of traders like to get in well before a large spike, so it's always a smart move to monitor unusual volume. That said, remember to combine trend and price action with unusual volume. Put them all together to help you decipher the next big trend for any stock.

>>5 Stocks With Big Insider Buying

With that in mind, let's take a look at several stocks rising on unusual volume today.

Santarus

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Santarus ( SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. This stock closed up 9.6% to $27.26 in Wednesday's trading session.

Wednesday's Volume: 6.36 million
Three-Month Average Volume: 1.44 million
Volume % Change: 396%

Shares of SNTS ripped higher on Wednesday after the company topped analysts' second-quarter estimates and raised its guidance. Sales rose 89% to $89 million, beating estimates by $6 million.

>>5 Stocks Ready to Break Out

From a technical perspective, SNTS gapped sharply higher here into new all-time high territory with monster upside volume. This stock has been uptrending extremely strong for the last six months, with shares soaring higher from its low of $12.65 to its new all-time high of $28.10. During that move, shares of SNTS have been consistently making higher lows and higher highs, which is bullish technical price action.

Traders should now look for long-biased trades in SNTS as long as it's trending above Wednesday's low of $26.25 and then once it sustains a move or close above its all-time high at $28.10 with volume that hits near or above 1.44 million shares. If we get that move soon, then SNTS will set up to enter new all-time-high territory, which is bullish technical price action. Some possible upside targets off that move are $35 to $37.

Amgen

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Amgen ( AMGN) is a biotechnology medicines company. It discovers, develops, manufactures and delivers innovative human therapeutics. This stock closed up 6.8% at $112.40 in Wednesday's trading session.

Wednesday's Volume: 9.91 million
Three-Month Average Volume: 3.27 million
Volume % Change: 189%

Shares of AMGN ripped higher on Wednesday after news broke that the company is close to a deal to buy Onyx Pharmaceuticals (ONXX) for $130 a share, valuing the deal at around $9.5 billion.

>>5 Biotech Stocks Under $10 Making Big Moves

From a technical perspective, AMGN spiked sharply higher here right above its 50-day moving average of $102.08 with heavy upside volume. This move pushed shares of AMGN into breakout territory, since it took out some near-term overhead resistance levels at $110 to $111.30. Shares of AMGN are now quickly moving within range of triggering another big breakout trade. That trade will hit if AMGN manages to take out Wednesday's high of $113.30 to its 52-week high at $114.95 with high volume.

Traders should now look for long-biased trades in AMGN as long as it's trending above $110 or $108 and then once it sustains a move or close above those breakout levels with volume that hits near or above 3.27 million shares. If that breakout hits soon, then AMGN will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside targets off that move are $120 to $125.

Jazz Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Jazz Pharmaceuticals ( JAZZ) is a specialty pharmaceutical company, which is focused on developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. This stock closed up 3.5% at $80.73 in Wednesday's trading session.

Wednesday's Volume: 1.50 million
Three-Month Average Volume: 950,117
Volume % Change: 70%

>>5 Rocket Stocks Set to Rally

From a technical perspective, JAZZ surged higher here right above some near-term support at $75 and into new 52-week-high territory with strong upside volume. This stock has been uptrending very strong for the last three months, with shares soaring higher from its low of $53.29 to its intraday high of $81.25. During that move, shares of JAZZ have been consistently making higher lows and higher highs, which is bullish technical price action.

Traders should now look for long-biased trades in JAZZ as long as it's trending above $75 and then once it sustains a move or close above its new 52-week high at $81.25 with volume that's near or above 950,117 shares. If we get that move soon, then JAZZ will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $85 to $90.

To see more stocks rising on unusual volume, check out the Stocks Rising On Unusual Volume portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including
CNBC.com and Forbes.com . You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.

More from Investing

Here Is Your Market Playbook During This Tariff-Driven Selloff

Here Is Your Market Playbook During This Tariff-Driven Selloff

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

Dropbox Is the New Defensive Stock to Own With the Market Falling Apart

The Quick Answer Why Trump's Trade War Makes Stocks at Least 10% Overvalued

The Quick Answer Why Trump's Trade War Makes Stocks at Least 10% Overvalued

Marriott CEO on Tax Cuts, Trade War Worries and China's Economy

Marriott CEO on Tax Cuts, Trade War Worries and China's Economy

50 Stocks Goldman Sachs Thinks Can Triumph Over Wage Inflation

50 Stocks Goldman Sachs Thinks Can Triumph Over Wage Inflation